Context Therapeutics to Participate in Two April 2023 Investor Conferences
April 03 2023 - 7:30AM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a biopharmaceutical company developing novel treatments for
solid tumors, today announced that Chief Executive Officer Martin
Lehr will participate virtually in two investor conferences in
April 2023. Details of the events are as follows:
- Diamond Equity Emerging Growth Invitational Investor
Conference: The Company will present on Wednesday, April 5
at 9:40 a.m. ET. To register for the event, please click here.
- 22nd Annual Needham
Virtual Healthcare Conference: The Company will
present on Wednesday, April 19 at 8:45 a.m. ET. Context will also
participate in one-on-one meetings.
About Context Therapeutics®Context
Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical
company committed to advancing medicines for solid tumors. Context
is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3
bispecific antibody for CLDN6-positive tumors, currently in
preclinical development. Context is headquartered in Philadelphia.
For more information, please
visit www.contexttherapeutics.com or follow the Company
on Twitter and LinkedIn.
Forward-looking StatementsThis
press release contains “forward-looking statements” that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Any statements, other than statements of historical fact, included
in this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the ability of the Company and its
employees to participate in and present at conferences, (ii) the
results of our clinical trials, (iii) the potential benefits of our
product candidate, (iv) the likelihood data will support future
development, and (v) the likelihood of obtaining regulatory
approval of our product candidate. Forward-looking statements in
this release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine
YonkerEdison Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024